Latest News
JCR Pharmaceuticals invests in Mycenax Biotech, becomes largest shareholder

Source: Mycenax Biotech

Mycenax Biotech (TWO: 4726), a pioneer in Taiwan for biopharmaceutical CDMO services, announced today that the board of directors has finalized plans for private placement.

This private placement focused on a few key investors, of which JCR Pharmaceuticals Co., Ltd., a distinguished Japanese biopharmaceutical company, has become the largest shareholder (20.48%), followed by CENTER Laboratories, Inc. (20.46%).

In this private placement, JCR Pharmaceuticals Co., Ltd. purchased 42,000,000 shares and CENTER Laboratories, Inc. purchased 8,000,000 shares with a price at 32.5 NTD per share. The private placement was expected to reach a total amount of 1,625,000,000 NTD (~54.3 million USD).

For full release please visit

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
© 2024 Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978